A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01484561
First received: November 30, 2011
Last updated: March 4, 2014
Last verified: March 2014
  Purpose

The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).


Condition Intervention Phase
Arthritis, Rheumatoid
Drug: CP-690,550 or Placebo
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Adjusted Geometric (Geo) Mean-Fold Change at End of Period 1 From Baseline in Measured Glomerular Filtration Rate (mGFR) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: Yes ]
    Glomerular filtration rate (GFR) is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. mGFR was determined using iohexol serum clearance using compartmental modeling of the iohexol serum concentration-time data. mGFR values were normalized to 1.73 meters squared (m^2) body surface area. A normal GFR is greater than (>)90 milliliters per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR <15 mL/min is consistent with kidney failure. Baseline was defined as the mean of the values obtained at Run-in and on predose in Period 1/Day 1.


Secondary Outcome Measures:
  • Adjusted Geometric Mean-Fold Change at the End of Period 2 From Baseline in mGFR [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    mGFR was determined using iohexol serum clearance using compartmental modeling of the iohexol serum concentration-time data. mGFR values were normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Run-in and on predose in Period 1/Day 1.

  • Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in mGFR [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    mGFR was determined using iohexol serum clearance using compartmental modeling of the iohexol serum concentration-time data. mGFR values were normalized to 1.73 m^2 body surface area.

  • Adjusted Geometric Mean-Fold Change at End of Period 1 From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using Modified Diet in Renal Disease (MDRD) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: Yes ]
    eGFR was calculated using the MDRD equation and normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.

  • Adjusted Geometric Mean-Fold Change at End of Period 2 From Baseline in eGFR Using MDRD [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    eGFR was calculated using the MDRD equation with eGFR values normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.

  • Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in eGFR Using MDRD [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    eGFR was calculated using the MDRD equation with eGFR values normalized to 1.73 m^2 body surface area.

  • Adjusted Geometric Mean-Fold Change at End of Period 1 From Baseline in eGFR Using the Cockcroft-Gault Equation [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: Yes ]
    eGFR was calculated using the Cockcroft-Gault equation normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.

  • Adjusted Geometric Mean-Fold Change at End of Period 2 From Baseline in eGFR Using the Cockcroft-Gault Equation [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    eGFR was calculated using the Cockcroft-Gault equation normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.

  • Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in eGFR Using the Cockcroft-Gault Equation [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    eGFR was calculated using the Cockcroft-Gault equation normalized to 1.73 m^2 body surface area.

  • Adjusted Geometric Mean-Fold Change at End of Period 1 From Baseline in Serum Creatinine [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: Yes ]
    Blood samples were collected from participants at screening, predose on Day 1 of Period 1, on the last day of Period 1 and on the last day of Period 2 for assessment of serum creatinine levels. Serum creatinine values in milligrams per deciliter (mg/dL) reported by the central laboratory were used. Baseline for serum creatinine was defined as the mean of values obtained at screening and predose on Day 1 of Period 1.

  • Adjusted Geometric Mean-Fold Change From End of Period 2 From Baseline in Serum Creatinine [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    Blood samples were collected from participants at screening, predose on Day 1 of Period 1, on the last day of Period 1 and on the last day of Period 2 for assessment of serum creatinine levels. Serum creatinine values in mg/dL reported by the central laboratory were used. Baseline for serum creatinine was defined as the mean of values obtained at screening and predose on Day 1 of Period 1.

  • Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in Serum Creatinine [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: Yes ]
    Blood samples were collected from participants at screening, predose on Day 1 of Period 1, on the last day of Period 1 and on the last day of Period 2 for assessment of serum creatinine levels. Serum creatinine values in mg/dL reported by the central laboratory were used.

  • Percentage of Participants Achieving an American College of Rheumatology 20% (ACR20) Response [ Time Frame: Day 1 of Period 1 to Day 43 of Period 1, Day 1 of Period 1 to Day 29 of Period 2 ] [ Designated as safety issue: No ]
    ACR20 response: greater than or equal to (≥)20 percent (%) improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).

  • Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response [ Time Frame: Day 1 of Period 1 to Day 43 of Period 1, Day 1 of Period 1 to Day 29 of Period 2 ] [ Designated as safety issue: No ]
    ACR50 response: ≥50% improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a HAQ, and 5) CRP at each visit.

  • Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response [ Time Frame: Day 1 of Period 1 to Day 43 of Period 1, Day 1 of Period 1 to Day 29 of Period 2 ] [ Designated as safety issue: No ]
    ACR70 response: ≥70% improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant' assessment of functional disability via a HAQ, and 5) CRP at each visit.

  • Least Squares (LS) Mean Change at End of Period 1 From Baseline in Disease Activity Score Based on 28-Joint Count CRP (DAS28-3 [CRP]) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    DAS28 calculated from the tender/painful joint count, swollen joint count (SJC) using the 28 joints count, and CRP value. DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (>)3.2 to 5.1 = moderate to high disease activity.

  • LS Mean Change at End of Period 2 From Baseline in DAS28-3 (CRP) [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    DAS28 calculated from the tender/painful joint count, SJC using the 28 joints count, and CRP value. DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.

  • LS Mean Change at End of Period 2 From End of Period 1 in DAS28-3 (CRP) [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    DAS28 calculated from the tender/painful joint count, SJC using the 28 joints count, and CRP value. DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.

  • LS Mean Change at End of Period 1 From Baseline DAS28-4 (CRP) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    DAS28 calculated from the number of SJC and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.

  • LS Mean Change at End of Period 2 From Baseline DAS28-4 (CRP) [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    DAS28 calculated from the number of SJC and PJC using the 28 joints count, the ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.

  • LS Mean Change at End of Period 2 From End of Period 1 DAS28-4 (CRP) [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    DAS28 calculated from the number of SJC and PJC using the 28 joints count, the ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.

  • LS Mean Change at End of Period 1 From Baseline in Tender/Painful Joint Count [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    68 joints were assessed by a joint assessor to determine the number of joints that were considered tender or painful Assessed joints included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb interphalangeal [IP], PIP, and distal interphalangeals [DIP]), and lower extremity (hip, knee, ankle, tarsus, metatarsophalangeals [MTP], great toe IP, proximal and distal interphalangeals combined [PIP]).

  • LS Mean Change at End of Period 2 From Baseline in Tender/Painful Joint Count [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    68 joints were assessed by a joint assessor to determine the number of joints that were considered tender or painful Assessed joints included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (hip, knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).

  • LS Mean Change at End of Period 2 From End of Period 1 in Tender/Painful Joint Count [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    68 joints were assessed by a joint assessor to determine the number of joints that were considered tender or painful Assessed joints included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (hip, knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).

  • LS Mean Change at End of Period 1 From Baseline in Swollen Joint Count [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    Swollen joint count included 66 joints. Assessor assessed joints for swelling using the following scale: present/absent/not done/not applicable (to be used for artificial joints). Joints assessed included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).

  • LS Mean Change at End of Period 2 From Baseline in Swollen Joint Count [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    Swollen joint count included 66 joints. Assessor assessed joints for swelling using the following scale: present/absent/not done/not applicable (to be used for artificial joints). Joints assessed included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).

  • LS Mean Change at End of Period 2 From End of Period 1 in Swollen Joint Count [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    Swollen joint count included 66 joints. Assessor assessed joints for swelling using the following scale: present/absent/not done/not applicable (to be used for artificial joints). Joints assessed included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).

  • LS Mean Change at End of Period 1 From Baseline in CRP [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
  • LS Mean Change at End of Period 2 From Baseline in CRP [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
  • LS Mean Change at End of Period 2 From End of Period 1 in CRP [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
  • LS Mean Change at End of Period 1 From Baseline in Patient Global Assessment of Arthritis (PGAA) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 millimeter (mm) visual analog scale (VAS), where 0 mm = very well and 100 mm = very poorly.

  • LS Mean Change at End of Period 2 From Baseline in PGAA [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participants responses were recorded using a 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

  • LS Mean Change at End of Period 2 From End of Period 1 in PGAA [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participants responses were recorded using a 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

  • LS Mean Change at End of Period 1 From Baseline in Physician Global Assessment of Arthritis [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    A physician assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination. The physician's response was recorded using a 100 mm VAS, where 0 mm = very good and 100 mm = very poor.

  • LS Mean Change at End of Period 2 From Baseline in Physician Global Assessment of Arthritis [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    A physician assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination. The physician's response was recorded using a 100 mm VAS, where 0 mm = very good and 100 mm = very poor.

  • LS Mean Change at End of Period 2 From End of Period 1 in Physician Global Assessment of Arthritis [ Time Frame: Day 43 of Period 1, Day 29 of Period 1 ] [ Designated as safety issue: No ]
    A physician assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination. The physician's response was recorded using a 100 mm VAS, where 0 mm = very good and 100 mm = very poor.

  • LS Mean Change at End of Period 1 From Baseline in Patient Assessment of Arthritis Pain [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    Participant's assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

  • LS Mean Change at End of Period 2 From Baseline in Patient Assessment of Arthritis Pain [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    Participant's assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

  • LS Mean Change at End of Period 2 From End of Period 1 in Patient Assessment of Arthritis Pain [ Time Frame: Day 43 of Period 2, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    Participant's assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

  • LS Mean Change at End of Period 1 From Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) Score [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ] [ Designated as safety issue: No ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

  • LS Mean Change at End of Period 2 From Baseline HAQ-DI Score [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

  • LS Mean Change at End of Period 2 From End of Period 1 HAQ-DI Score [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ] [ Designated as safety issue: No ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.


Enrollment: 148
Study Start Date: April 2012
Study Completion Date: February 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sequence 1 Drug: CP-690,550 or Placebo
CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
Placebo Comparator: Sequence 2 Drug: Placebo
Placebo BID orally, approximately 72 days

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the seven criteria.
  • The patient must have active disease at both Screening and predose on Day 1 of Period 1.
  • Patient must have had an inadequate response to at least one disease-modifying antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or intolerance.

Exclusion Criteria:

  • Pregnant or lactating women
  • Serious medical conditions that would make treatment with CP-690,550 potentially unsafe.
  • A patient who has a history of asthma, multiple allergies or severe allergy (eg, anaphylaxis) to any substance. In particular, a history of allergy to iodine, povidone-iodine, iohexol or other iodinated contrast media.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01484561

Locations
United States, Florida
Pfizer Investigational Site
South Miami, Florida, United States, 33143
United States, New York
Pfizer Investigational Site
Albany, New York, United States, 12206
United States, Pennsylvania
Pfizer Investigational Site
Duncansville, Pennsylvania, United States, 16635
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75231
United States, Washington
Pfizer Investigational Site
Tacoma, Washington, United States, 98405
Czech Republic
Pfizer Investigational Site
Praha 4, Czech Republic, 140 59
Germany
Pfizer Investigational Site
Berlin, Germany, 13125
Pfizer Investigational Site
Erlangen, Germany, 91054
Pfizer Investigational Site
Wuerzburg, Germany, 97080
Korea, Republic of
Pfizer Investigational Site
Seoul, Korea, Republic of, 120-752
Mexico
Pfizer Investigational Site
Merida, Yucatan, Mexico, 97000
Poland
Pfizer Investigational Site
Bialystok, Poland, 15-354
Pfizer Investigational Site
Bydgoszcz, Poland, 85-168
Pfizer Investigational Site
Warszawa, Poland, 02-256
Pfizer Investigational Site
Warszawa, Poland, 01-192
Pfizer Investigational Site
Wroclaw, Poland, 50-088
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation, 115522
Pfizer Investigational Site
Petrozavodsk, Russian Federation, 185019
Pfizer Investigational Site
Saint Petersburg, Russian Federation, 197341
Pfizer Investigational Site
St. Petersburg, Russian Federation, 194291
Spain
Pfizer Investigational Site
Barakaldo, Vizcaya, Spain, 48903
Pfizer Investigational Site
Bilbao, Vizcaya, Spain, 48013
Pfizer Investigational Site
La Coruna, Spain, 15006
Pfizer Investigational Site
Sevilla, Spain, 41009
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01484561     History of Changes
Other Study ID Numbers: A3921152
Study First Received: November 30, 2011
Results First Received: January 11, 2014
Last Updated: March 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Phase 1

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Tofacitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 01, 2014